본문 바로가기

Randomized, Controlled, Multi-center Trial: Comparing the Safety and Efficacy of DA-9701 and Itopride Hydrochloride in Patients With Functional Dyspepsia

문서 유형
연구출판물 · 학술지 논문
등재
KCISCIEScopus
저널 순위
JCR Q3Scopus Q1
피인용
Web of Science 29KCI 9
JCR IF
JCR 2014 2.296
ISSN
2093-0879

저자

  1. 최명규제1저자가톨릭대학교
  2. 이풍렬성균관대학교
  3. 박효진연세대학교
  4. 이오영한양대학교
  5. 이광재아주대학교
  6. 최석채원광대학교
  7. 설상영인제대학교
  8. 전훈재고려대학교
  9. 유종선전남대학교
  10. 이동호서울대학교
  11. 송근암부산대학교
  12. 정훈영울산대학교
  13. 정현용충남대학교
  14. 성인경건국대학교
  15. 이준성순천향대학교
  16. 이수택전북대학교
  17. 김성국경북대학교
  18. 신용운인하대학교

초록

Background/Aims Therapies of functional dyspepsia (FD) are limited. DA-9701 is a novel prokinetic agent formulated with Pharbitis semen and Corydalis Tuber. We aimed to assess the efficacy of DA-9701 compared with itopride in FD patients. Methods Patients with FD. randomly received either itopride 50 mg or DA-9701 30 mg t.i.d after a 2-week baseline period. After 4 weeks of treatment, 2 primary efficacy endpoints were analyzed: the change from baseline in composite score of the 8 dyspeptic symptoms and the overall treatment effect. Impact on patients' quality of life was assessed using the Nepean Dyspepsia Index (NI) questionnaire. Results We randomly assigned 464 patients with 455 having outcome data. The difference of the composite score change of the 8 symptoms between the 2 groups was 0.62, indicating that DA-9701 was not inferior to itopride. The overall treatment effect response rate was not different between the groups. When responder was defined as >= 5 of the 7 Likert scale, responder rates were 37% of DA-9701 and 36% of itopride group. Patients receiving DA-9701 experienced similar mean percentage of days with adequate relief during the 4-week treatment period compared with those receiving itopride (56.8% vs 59.1%). Both drugs increased the NDI score of 5 domains without any difference in change of the NDI score between the groups. The safety profile of both drugs was comparable. Conclusions DA-9701 significantly improves symptoms in patients with FD. DA-9701 showed non-inferior efficacy to itopride with comparable safety.

키워드

Clinical trialDA-9701Functional dyspepsiaItoprideQUALITY-OF-LIFEPROKINETIC AGENTGASTROINTESTINAL DISORDERSNEPEAN DYSPEPSIACORYDALIS TUBERMOTOR FUNCTIONLONG-TERMSCALEINDEXCELLS

식별자

WoS UID
000357708500014
KCI
ART002016199